Review anchor
Mitogen-activated protein kinase kinase kinase 19
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Mitogen-activated protein kinase kinase kinase 19
CHEMBL6191
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Mitogen-activated protein kinase kinase kinase 19 as ChEMBL target CHEMBL6191, mapped to UniProt Q56UN5. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL6191
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q56UN5
Mitogen-activated protein kinase kinase kinase 19
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Mitogen-activated protein kinase kinase kinase 19 matters
Mitogen-activated protein kinase kinase kinase 19 is reviewed as Mitogen-activated protein kinase kinase kinase 19 (UniProt Q56UN5); the current evidence base includes 16 approved drugs, 314 compounds, and 125 assays, with lead potency reaching pChEMBL 9.3.
Protein context
Mitogen-activated protein kinase kinase kinase 19
Mitogen-activated protein kinase kinase kinase 19 Sequence length is 1328 aa.
Review this target as Mitogen-activated protein kinase kinase kinase 19, mapped to UniProt Q56UN5. Sequence length is 1328 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q56UN5
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 16 approved drugs, 314 compounds, and 125 assays for this target. The dominant activity type is KD. CHEMBL603469 is the current potency anchor at pChEMBL 9.3.
Use CHEMBL603469 as the tractability anchor when discussing potency (pChEMBL 9.3).
Activity source · ChEMBL 36 via Core Engine
16 approved
pChEMBL 9.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Mitogen-activated protein kinase kinase kinase 19 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q56UN5, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
314
Total Compounds
125
Total Assays
16
Approved Drugs
IC50: 26.0, KD: 96.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL603469
|
9.3 | Kd | Clinical |
|
|
No preferred name
CHEMBL388978
|
9.1 | Kd | — |
|
|
No preferred name
CHEMBL4290597
|
8.9 | Kd | — |
|
|
No preferred name
CHEMBL388978
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL1241674
|
8.3 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
QUIZARTINIB
CHEMBL576982
|
2023 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
AXITINIB
CHEMBL1289926
|
2012 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
GEFITINIB
CHEMBL939
|
2003 |
Source Header